首頁 > 市場調查報告書 > 製藥

癌症婦科治療

市場調查報告書

商品編碼

1541355

2024-2032 年按類型、治療類型、最終用戶和地區分類的卵巢癌市場報告

Ovarian Cancer Market Report by Type, Treatment Type, End User, and Region 2024-2032

出版日期: 2024年08月10日 | 出版商:

IMARC | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

IMARC Group年全球卵巢癌市場規模達21億美元。卵巢癌發生率的上升、癌症護理中個人化醫療的出現以及政府提高意識、促進早期檢測和支持研究的舉措的實施是推動市場的一些關鍵因素。

卵巢癌是一種始於卵巢的癌症，卵巢是負責產生卵子和雌性荷爾蒙的女性生殖器官。當卵巢中的異常細胞不受控制地生長和繁殖並形成腫瘤時，通常會發生這種情況。卵巢癌有不同類型，可以根據其起源的特定細胞進行分類。最常見的類型是上皮性卵巢癌，它起源於卵巢表面。其他較不常見的類型包括生殖細胞腫瘤和間質腫瘤，它們分別由產生卵子和荷爾蒙的細胞發展而來。卵巢癌的常見症狀包括腹脹、骨盆或腹部疼痛、進食困難或很快就感到飽、頻尿和排便習慣改變。

全球卵巢癌發生率不斷上升推動了市場的發展。卵巢癌發生率的上升促使醫療保健提供者和製藥公司大力投資研發，以發現創新療法和標靶治療。此外，醫療技術和診斷技術的進步導致了卵巢癌的早期檢測和診斷，使醫療保健專業人員能夠在早期階段開始治療，改善患者的治療結果並提高存活率。此外，一般民眾和醫療保健專業人員對定期篩檢和早期檢測重要性的認知不斷增強，對於降低卵巢癌相關死亡率發揮著至關重要的作用。此外，製藥公司和研究機構之間的策略合作和夥伴關係為開發新型療法和個人化治療方案鋪平了道路。此外，一些地區醫療基礎設施投資的不斷增加以及優惠報銷政策的訂定，鼓勵卵巢癌患者及時尋求全面治療。

卵巢癌市場趨勢/促進因素：

卵巢癌盛行率不斷上升

卵巢癌盛行率的不斷上升是塑造全球卵巢癌市場動態的主要動力。卵巢癌是影響全世界女性最常見的婦科惡性腫瘤之一。據世界衛生組織 (WHO) 稱，每年診斷出數以千計的新病例，使其成為重大的健康問題。人口老化和生活方式的改變，包括久坐的習慣和不健康的飲食，導致卵巢癌發生率上升。隨著人口老化，罹患卵巢癌的風險增加，進一步增加了對有效治療方案的需求。卵巢癌病例的激增刺激了製藥公司和研究機構的廣泛研究和開發工作，這正在影響市場的成長。

醫療技術和個人化醫療的技術進步

醫療技術和個人化醫療的進步開創了卵巢癌治療的新時代，成為市場的重要動力。診斷工具和影像方式已經顯著發展，使得卵巢癌的早期檢測和準確診斷成為可能。經陰道超音波、磁振造影 (MRI) 和血清生物標記檢測（例如 CA-125）提高了早期發現卵巢癌的機會，並提高了成功治療的前景。此外，個人化醫療的興起改變了癌症治療的方法，包括卵巢癌。標靶療法和免疫療法的發展徹底改變了癌症治療，提供針對個別患者腫瘤的特定分子和遺傳特徵的客製化治療。這些精準治療在臨床試驗中顯示出有希望的結果，為先前治療選擇有限的卵巢癌患者帶來了新的希望。

落實優惠報銷政策

醫療基礎設施的擴張和優惠報銷政策的存在在推動全球卵巢癌市場的成長中發揮了關鍵作用。各國政府和醫療機構擴大投資於加強醫療設施，包括癌症治療中心和腫瘤科。這一發展顯著改善了卵巢癌患者獲得醫療保健服務、診斷和治療的機會。此外，優惠的報銷政策減輕了尋求癌症治療的患者的經濟負擔。對診斷測試、手術、化療和標靶治療的報銷支持使更廣泛的人群更負擔得起並更容易獲得治療。

The global ovarian cancer market size reached US$ 2.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.1 Billion by 2032, exhibiting a growth rate (CAGR) of 10.09% during 2024-2032. The rising incidence of ovarian cancer cases, the emergence of personalized medicine in cancer care, and the implementation of government Initiatives to raise awareness, promote early detection, and support research represent some of the key factors driving the market.

Ovarian cancer is a type of cancer that begins in the ovaries, the female reproductive organs responsible for producing eggs and female hormones. It typically develops when abnormal cells in the ovaries grow and multiply uncontrollably, forming a tumor. There are different types of ovarian cancer, and they can be classified based on the specific cells from which they originate. The most common type is epithelial ovarian cancer, which arises from the surface of the ovary. Other less common types include germ cell tumors and stromal tumors, which develop from the cells that produce eggs and hormones, respectively. Common symptoms of ovarian cancer include abdominal bloating, pelvic or abdominal pain, difficulty eating or feeling full quickly, frequent urination, and changes in bowel habits.

The market is driven by the increasing prevalence of ovarian cancer cases globally. The rising incidence of ovarian cancer has prompted healthcare providers and pharmaceutical companies to invest heavily in research and development to discover innovative therapies and targeted treatments. Moreover, advancements in medical technology and diagnostic techniques have led to early detection and diagnosis of ovarian cancer, enabling healthcare professionals to initiate treatment at earlier stages, improving patient outcomes, and enhancing survival rates. Besides, the growing awareness among the general population and healthcare professionals about the importance of regular screenings and early detection plays a crucial role in reducing mortality rates associated with ovarian cancer. Additionally, strategic collaborations and partnerships between pharmaceutical companies and research institutions have paved the way for the development of novel therapeutics and personalized treatment options. Furthermore, the rising investment in healthcare infrastructure and the availability of favorable reimbursement policies in several regions have encouraged patients to seek timely and comprehensive treatment for ovarian cancer.

Ovarian Cancer Market Trends/Drivers:

Growing prevalence of ovarian cancer

The escalating prevalence of ovarian cancer is a primary driver shaping the dynamics of the global ovarian cancer market. Ovarian cancer is one of the most common gynecologic malignancies affecting women worldwide. According to the World Health Organization (WHO), thousands of new cases are diagnosed each year, making it a significant health concern. The aging population and changing lifestyle patterns, including sedentary habits and unhealthy diets, have contributed to the rising incidence of ovarian cancer. As the population ages, the risk of developing ovarian cancer increases, further intensifying the demand for effective treatment options. This surge in ovarian cancer cases has spurred extensive research and development efforts by pharmaceutical companies and research institutions, which is influencing the market growth.

Technological advancements in medical technology and personalized medicine

Advancements in medical technology and personalized medicine have ushered in a new era in the management of ovarian cancer, constituting a significant driver in the market. Diagnostic tools and imaging modalities have evolved significantly, enabling early detection and accurate diagnosis of ovarian cancer. Transvaginal ultrasounds, magnetic resonance imaging (MRI), and serum biomarker tests, such as CA-125, have improved the chances of detecting ovarian cancer at its early stages, enhancing the prospects for successful treatment. Moreover, the rise of personalized medicine has transformed the approach to cancer treatment, including ovarian cancer. The development of targeted therapies and immunotherapies has revolutionized cancer care, offering tailored treatments that address the specific molecular and genetic characteristics of individual patients' tumors. These precision treatments have shown promising results in clinical trials, providing new hope for ovarian cancer patients who may have previously had limited treatment options.

Implementation of favorable reimbursement policies

The expansion of healthcare infrastructure and the presence of favorable reimbursement policies have played a pivotal role in driving the growth of the global ovarian cancer market. Governments and healthcare authorities in various countries are increasingly investing in bolstering healthcare facilities, including cancer treatment centers and oncology units. This development has significantly improved patient access to healthcare services, diagnosis, and treatment for ovarian cancer. Furthermore, favorable reimbursement policies have alleviated the financial burden on patients seeking cancer treatments. Reimbursement support for diagnostic tests, surgeries, chemotherapy, and targeted therapies has made treatment more affordable and accessible to a broader segment of the population.

Ovarian Cancer Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global ovarian cancer market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on type, treatment type and end user.

Breakup by Type:

Epithelial Ovarian Cancer

Germ Cell Ovarian Cancer

Stromal Cell Ovarian Cancer

Epithelial ovarian cancer represents the leading type

The report has provided a detailed breakup and analysis of the market based on the type. This includes epithelial ovarian cancer, germ cell ovarian cancer, and stromal cell ovarian cancer. According to the report, epithelial ovarian cancer represented the largest segment.

Epithelial ovarian cancer is more commonly diagnosed in older women, and as the global population ages, the incidence of ovarian cancer tends to increase. The risk of developing ovarian cancer rises significantly after menopause, making postmenopausal women more susceptible to this type of cancer. Moreover, obesity and unhealthy lifestyle choices, such as poor diet and lack of physical activity, have been associated with an increased risk of ovarian cancer. The global rise in obesity rates over the past few decades may have contributed to the growing prevalence of epithelial ovarian cancer. Besides, certain genetic mutations, such as BRCA1 and BRCA2 mutations, are known to increase the risk of developing ovarian cancer. Inherited genetic factors can play a significant role in the prevalence of epithelial ovarian cancer, especially in families with a history of the disease.

Breakup by Treatment Type:

Immunotherapy

Chemotherapy

Targeted Therapy

Surgery

Others

Immunotherapy is the most popular treatment type

A detailed breakup and analysis of the market based on the treatment type has also been provided in the report. This includes lateral flow assays, dipsticks, microfluidics, molecular diagnostics, and immunoassays. According to the report, lateral flow assays hold the largest market share.

Immunotherapy has emerged as a revolutionary approach in cancer treatment, showing promising results in various cancer types. Ovarian cancer, being one of the deadliest gynecological malignancies, has been a focus of research to identify novel and more effective therapies. Immunotherapy's success in other cancer types has generated significant interest in exploring its potential benefits in ovarian cancer treatment. Moreover, immunotherapy focuses on targeting the tumor microenvironment, which includes various immune cells and signaling molecules that support tumor growth and progression. By modulating the immune response, immunotherapy aims to create an inhospitable environment for cancer cells, hindering their growth and spread.

Breakup by End User:

Hospitals

Homecare

Speciality Centre

Others

The report has provided a detailed breakup and analysis of the market based on end user. This includes hospitals, homecare, speciality centre, and others.

Hospitals are the primary healthcare institutions that play a crucial role in the diagnosis, treatment, and management of ovarian cancer. They offer a comprehensive range of medical services, including surgery, chemotherapy, radiation therapy, and supportive care for ovarian cancer patients. Hospitals typically have specialized oncology departments or cancer centers equipped with advanced medical technology and a multidisciplinary team of healthcare professionals, including oncologists, surgeons, nurses, and support staff.

Homecare services may include nursing care, administration of medications, pain management, wound care, and assistance with activities of daily living. Homecare is particularly beneficial for patients who require ongoing support and monitoring but prefer to receive treatment in a familiar environment. Homecare services aim to enhance the quality of life for ovarian cancer patients, allowing them to remain in their homes while receiving necessary medical attention.

Specialty centers are dedicated healthcare facilities that focus on specific medical conditions or diseases, including ovarian cancer. These centers offer specialized expertise, state-of-the-art facilities, and advanced treatment options tailored to the needs of ovarian cancer patients. Specialty centers include oncology clinics, cancer institutes, and women's health centers that provide comprehensive care, support, and access to cutting-edge therapies and clinical trials for ovarian cancer.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America accounts for the majority of market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (United States, Canada); Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others); Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others); Latin America (Brazil, Mexico, Others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America boasts a well-established and technologically advanced healthcare infrastructure, with a high concentration of hospitals, specialty centers, and cancer institutes equipped with state-of-the-art medical facilities and cutting-edge technologies. This enables efficient diagnosis, treatment, and follow-up care for ovarian cancer patients. Moreover, the region is a hub for biomedical research and development, with numerous pharmaceutical and biotechnology companies conducting extensive research on cancer therapies, including ovarian cancer. Ongoing research and clinical trials contribute to the development of innovative treatment options and novel drugs, making North America a frontrunner in ovarian cancer treatment advancements.

Competitive Landscape:

The competitive landscape of the ovarian cancer market is characterized by a mix of pharmaceutical companies, biotechnology firms, and academic institutions actively engaged in research, development, and commercialization of treatments and therapies. These companies are developing and commercializing chemotherapy drugs, targeted therapies, and immunotherapies for ovarian cancer treatment. They are also focusing on novel drug development and personalized treatment options. Moreover, various companies are identifying new drug targets, exploring combination therapies, and conducting clinical trials to assess the safety and efficacy of their investigational drugs. They are also forming strategic partnerships with academic institutions, research organizations, and other biopharmaceutical firms to access complementary expertise, resources, and technologies.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AbbVie Inc.

Amneal Pharmaceuticals Inc.

AstraZeneca plc

Eli Lilly and Company

F. Hoffmann-La

Roche AG

GSK plc

Hikma Pharmaceuticals PLC

Lupin Limited

Pfizer Inc.

Teva Pharmaceutical Industries Ltd.

Recent Developments:

In September 2022, AstraZeneca and Merck jointly declared that Lynparza (olaparib) had received approval in China for the maintenance treatment of adult patients diagnosed with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. This approval applies specifically to patients who have shown a complete or partial response to 1st-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD)-positive status.

In September 2022, Pfizer and Strata Oncology announced an expansion of their partnership to include a clinical trial that will evaluate multiple cancer therapies in novel, biomarker-guided patient cohorts.

Tesaro, which is now part of GlaxoSmithKline (GSK), launched "Zejula" (niraparib), another PARP inhibitor, for the treatment of ovarian cancer. Zejula is indicated for maintenance treatment in women with recurrent ovarian cancer who have responded to platinum-based chemotherapy.

Key Questions Answered in This Report:

How has the global ovarian cancer market performed so far, and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global ovarian cancer market?
What is the impact of each driver, restraint, and opportunity on the global ovarian cancer market?
What are the key regional markets?
Which countries represent the most attractive ovarian cancer market?
What is the breakup of the market based on types?
Which is the most attractive types in the ovarian cancer market?
What is the breakup of the market based on treatment type?
Which is the most attractive treatment type in the ovarian cancer market?
What is the breakup of the market based on the end user?
Which is the most attractive end user in the ovarian cancer market?
What is the competitive structure of the global ovarian cancer market?
Who are the key players/companies in the global ovarian cancer market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Ovarian Cancer Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Type

6.1 Epithelial Ovarian Cancer
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Germ Cell Ovarian Cancer
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Stromal Cell Ovarian Cancer
- 6.3.1 Market Trends
- 6.3.2 Market Forecast

7 Market Breakup by Treatment Type

7.1 Immunotherapy
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Chemotherapy
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Targeted Therapy
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Surgery
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Others
- 7.5.1 Market Trends
- 7.5.2 Market Forecast

8 Market Breakup by End User

8.1 Hospitals
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Homecare
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Speciality Centre
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Others
- 8.4.1 Market Trends
- 8.4.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 SWOT Analysis

10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 AbbVie Inc.
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
  - 14.3.1.3 Financials
  - 14.3.1.4 SWOT Analysis
- 14.3.2 Amneal Pharmaceuticals Inc.
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
  - 14.3.2.3 Financials
- 14.3.3 AstraZeneca plc
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
  - 14.3.3.3 Financials
  - 14.3.3.4 SWOT Analysis
- 14.3.4 Eli Lilly and Company
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
  - 14.3.4.3 Financials
  - 14.3.4.4 SWOT Analysis
- 14.3.5 F. Hoffmann-La Roche AG
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio
  - 14.3.5.3 Financials
- 14.3.6 GSK plc
  - 14.3.6.1 Company Overview
  - 14.3.6.2 Product Portfolio
  - 14.3.6.3 Financials
  - 14.3.6.4 SWOT Analysis
- 14.3.7 Hikma Pharmaceuticals PLC
  - 14.3.7.1 Company Overview
  - 14.3.7.2 Product Portfolio
  - 14.3.7.3 Financials
  - 14.3.7.4 SWOT Analysis
- 14.3.8 Lupin Limited
  - 14.3.8.1 Company Overview
  - 14.3.8.2 Product Portfolio
  - 14.3.8.3 Financials
  - 14.3.8.4 SWOT Analysis
- 14.3.9 Pfizer Inc.
  - 14.3.9.1 Company Overview
  - 14.3.9.2 Product Portfolio
  - 14.3.9.3 Financials
  - 14.3.9.4 SWOT Analysis
- 14.3.10 Teva Pharmaceutical Industries Ltd.
  - 14.3.10.1 Company Overview
  - 14.3.10.2 Product Portfolio
  - 14.3.10.3 Financials
  - 14.3.10.4 SWOT Analysis

簡介目錄圖表

List of Figures

Figure 1: Global: Ovarian Cancer Market: Major Drivers and Challenges
Figure 2: Global: Ovarian Cancer Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Ovarian Cancer Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Ovarian Cancer Market: Breakup by Type (in %), 2023
Figure 5: Global: Ovarian Cancer Market: Breakup by Treatment Type (in %), 2023
Figure 6: Global: Ovarian Cancer Market: Breakup by End User (in %), 2023
Figure 7: Global: Ovarian Cancer Market: Breakup by Region (in %), 2023
Figure 8: Global: Ovarian Cancer (Epithelial Ovarian Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 9: Global: Ovarian Cancer (Epithelial Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 10: Global: Ovarian Cancer (Germ Cell Ovarian Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Ovarian Cancer (Germ Cell Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Ovarian Cancer (Stromal Cell Ovarian Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Ovarian Cancer (Stromal Cell Ovarian Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Ovarian Cancer (Immunotherapy) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Ovarian Cancer (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Ovarian Cancer (Chemotherapy) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Ovarian Cancer (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Ovarian Cancer (Targeted Therapy) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Ovarian Cancer (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Ovarian Cancer (Surgery) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Ovarian Cancer (Surgery) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Ovarian Cancer (Other Treatment Types) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Ovarian Cancer (Other Treatment Types) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: Global: Ovarian Cancer (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: Global: Ovarian Cancer (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: Global: Ovarian Cancer (Homecare) Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: Global: Ovarian Cancer (Homecare) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: Global: Ovarian Cancer (Speciality Centre) Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: Global: Ovarian Cancer (Speciality Centre) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: Global: Ovarian Cancer (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: Global: Ovarian Cancer (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: North America: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: North America: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: United States: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: United States: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: Canada: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: Canada: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: Asia-Pacific: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: Asia-Pacific: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: China: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: China: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: Japan: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: Japan: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: India: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: India: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: South Korea: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: South Korea: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: Australia: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: Australia: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: Indonesia: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: Indonesia: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: Others: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: Others: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: Europe: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: Europe: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: Germany: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: Germany: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: France: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: France: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: United Kingdom: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: United Kingdom: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: Italy: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: Italy: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: Spain: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: Spain: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: Russia: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: Russia: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: Others: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: Others: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 70: Latin America: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
Figure 71: Latin America: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 72: Brazil: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
Figure 73: Brazil: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 74: Mexico: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
Figure 75: Mexico: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 76: Others: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
Figure 77: Others: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 78: Middle East and Africa: Ovarian Cancer Market: Sales Value (in Million US$), 2018 & 2023
Figure 79: Middle East and Africa: Ovarian Cancer Market: Breakup by Country (in %), 2023
Figure 80: Middle East and Africa: Ovarian Cancer Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 81: Global: Ovarian Cancer Industry: SWOT Analysis
Figure 82: Global: Ovarian Cancer Industry: Value Chain Analysis
Figure 83: Global: Ovarian Cancer Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Ovarian Cancer Market: Key Industry Highlights, 2023 and 2032
Table 2: Global: Ovarian Cancer Market Forecast: Breakup by Type (in Million US$), 2024-2032
Table 3: Global: Ovarian Cancer Market Forecast: Breakup by Treatment Type (in Million US$), 2024-2032
Table 4: Global: Ovarian Cancer Market Forecast: Breakup by End User (in Million US$), 2024-2032
Table 5: Global: Ovarian Cancer Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 6: Global: Ovarian Cancer Market: Competitive Structure
Table 7: Global: Ovarian Cancer Market: Key Players

02-2729-4219

+886-2-2729-4219